ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,523.60
      1.05%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      -2.20%
      Bitcoin
      67,893.66
      3.20%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Amarin Corp PLC (AMRN) Quote

      Amarin Corp PLC

      Amarin Corp PLC (AMRN)

      NASDAQ
      0.7963
      0.0051
      (0.64%)
      At close: July 26 4:00PM
      Delayed by 15 minutes
      0.795
      -0.0013
      ( -0.16% )
      After Hours: 6:24PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      0.795
      Bid
      0.795
      Ask
      0.81
      Volume
      702,843
      0.7725 Day's Range 0.8183
      0.00 52 Week Range 0.00
      Market Cap
      326.641M
      Previous Close
      0.7912
      Open
      0.78
      Last Trade
      300
      @
      0.795
      (formt)
      Last Trade Time
      18:24:55
      Financial Volume
      $ 560,094
      VWAP
      0.796898
      Average Volume (3m)
      -
      Shares Outstanding
      410,868,659
      Dividend Yield
      -
      PE Ratio
      -
      Earnings Per Share (EPS)
      -
      Revenue
      -
      Net Profit
      -

      About Amarin Corp PLC

      Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa. Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.amarincorp.com
      Headquarters
      London, Gbr
      Founded
      1970
      Amarin Corp PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AMRN. The last closing price for Amarin was $0.79. Over the last year, Amarin shares have traded in a share price range of $ 0.00 to $ 0.00.

      Amarin currently has 410,868,659 shares outstanding. The market capitalization of Amarin is $325.08 million.

      AMRN Latest News

      More News

      Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

      -- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease...

      July 17 2024
      GlobeNewswire Inc.

      Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

      DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and...

      July 17 2024
      GlobeNewswire Inc.

      Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

      -- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride...

      July 08 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      June 04 2024
      Edgar (US Regulatory)

      Amarin Board of Directors Announces CEO Transition

      -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE...

      June 04 2024
      GlobeNewswire Inc.

       Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

      -- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml...

      May 28 2024
      GlobeNewswire Inc.

      Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

      DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer...

      May 06 2024
      GlobeNewswire Inc.

       Amarin Reports First Quarter 2024 Business Update and Financial Results

      -- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24...

      May 01 2024
      GlobeNewswire Inc.

      Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug...

      April 24 2024
      GlobeNewswire Inc.

      Amarin Announces Results of Annual General Meeting of Shareholders

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its...

      April 22 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CGTXCognition Therapeutics Inc
      $ 3.47
      (46.41%)
      		4.6M
      NAMSNewAmsterdam Pharma Company NV
      $ 22.49
      (19.25%)
      		18.82k
      RNAZTransCode Therapeutics Inc
      $ 0.341
      (15.36%)
      		6.61M
      YYGHYY Group Holding Ltd
      $ 0.84
      (14.60%)
      		743
      YIBOPlanet Image International Ltd
      $ 3.32
      (13.89%)
      		56.73k
      VTVTvTv Therapeutics Inc
      $ 13.00
      (-38.68%)
      		33.14k
      CEROCERo Therapeutics Holdings Inc
      $ 0.1669
      (-34.80%)
      		3.51M
      TGLTreasure Global Inc
      $ 1.32
      (-28.65%)
      		53.49k
      LUXHLuxUrban Hotels Inc
      $ 0.1587
      (-16.91%)
      		1.31M
      RGCRegencell Bioscience Holdings Ltd
      $ 10.69
      (-13.02%)
      		14.55k
      SLNASelina Hospitality PLC
      $ 0.0281
      (-6.33%)
      		23.11M
      RNAZTransCode Therapeutics Inc
      $ 0.341
      (15.36%)
      		6.61M
      CGTXCognition Therapeutics Inc
      $ 3.47
      (46.41%)
      		4.6M
      TLTiShares 20 plus Year Treasury Bond
      $ 92.94
      (-0.05%)
      		3.9M
      CEROCERo Therapeutics Holdings Inc
      $ 0.1669
      (-34.80%)
      		3.51M

      AMRN Discussion

      View Posts
      FlyFishingStocks FlyFishingStocks 2 hours ago
      "Stay with the program"? What's that supposed to mean? So are you saying Alex Denner (Sarissa) involvement had nothing to do with a -65% drop in the share price while the Bio index rose +65%. How is that "squirming past the facts? Do I need to remind you PRICE IS KING... PRICE IS FACT!

      Quit trying to bamboozle people into thinking you know what you’re talking about?

      The only person who has been bamboozled is you.
      👍️0
      Gusman Gusman 2 hours ago
      le pain et le loueil d'olive is optional It is one of the most beautiful towns I have been in and would recommend to anyone. Very close to Spain with just the Pyrenees to cross. Nice local vin yards.
      👍️0
      rosemountbomber rosemountbomber 2 hours ago
      Wow that’s as close to Spain as you can get. Never been to an anchovie bar - do they have bread and butter to go with that?

      Surely, they should recognize the value of EPA.
      👍️0
      ramfan60 ramfan60 3 hours ago
      Can only hope they nail this guy and other like him

      https://finance.yahoo.com/news/us-accuses-short-seller-andrew-125959087.html
      👍️0
      CaptBeer CaptBeer 3 hours ago
      Come on France! Pull your Head Out!
      👍️0
      Gusman Gusman 3 hours ago
      i spent the last two weeks in the south of France near Collioure and they have Bar À Anchois - Anchoive Bars - i was in heaven, white wine and Anchovies- its the EPA stupid

      But on a serious matter does Amarin have to overcome the Anchovies lobby to get reimbursement approval in France? O la la...
      👍️ 1 😁 1
      Number sleven Number sleven 6 hours ago
      https://gmmmg.nhs.uk/updated-lipid-pathway/
      Sleven,
      👍️ 2
      rosemountbomber rosemountbomber 7 hours ago
      Along with suggesting Icosapent Ethyl to those patients they should also suggest to the French govt agency in charge to hurry up with their reimbursement for Vazkepa.

      But like you say, slow but sure the data is mounting, and they eventually have to succumb.
      👍️ 1
      ramfan60 ramfan60 7 hours ago
      Nice find Sleven............. drip drip drip of good positive affirmation information
      👍️0
      Number sleven Number sleven 8 hours ago
      https://www.annalsofvascularsurgery.com/article/S0890-5096(23)00679-9/abstract
      Sleven,
      👍️ 1
      ORBAPU ORBAPU 9 hours ago
      About time. Hope others get indicted as well.

      https://www.wsj.com/finance/stocks/u-s-accuses-prominent-short-seller-andrew-left-of-fraud-0161e42f
      👍️ 2
      CaptBeer CaptBeer 9 hours ago
      Looks like VASCEPA®/VAZKEPA® safety profile in the Real World (RW) is significantly better than reported in the REDUCE-IT RCT & the labels in the USA & Europe. Check out these AE rate comparisons. VASCEPA®/VAZKEPA® = Safe & Effective.#IPE @SABOURETCardio @DLBHATTMD pic.twitter.com/QNelYdvOGU— Mike Everts (@GeoWizz_) July 26, 2024
      👍️ 1
      Nukemtiltheyglow Nukemtiltheyglow 10 hours ago
      I like how you squirm past the facts. Your question to Irish was about Alex Denner (Sarissa) involvement and who controlled Amarin’s destiny when the share price was last time @ $4.77?

      So, what’s happened since then is apparently in your perspective all Alex Denner & Sarissa’s fault? Really? Stay with the program. Quit trying to bamboozle people into thinking you know what you’re talking about?
      👍️ 1
      north40000 north40000 10 hours ago
      AMRN has traded more in line with the small-cap biotech index, not the XBI or even the Russell 2000 index. I picked AMRN as my top pick in a IHub contest of 10 savvy LT picks that began in early May and will end in late April or May 2025. My entry point for AMRN in the contest is $0.688. Other picks with entry values are CDMO= $7.14, ATNM= $7.40, AVXL= $4.22, MAGS= $45.11, MNMD= $7.21, NVDL= $69.55, NWBO= $0.428, VKTX= $53.01 and XERS= $2.25. None of those picks can be traded on a short term basis; all are LTBuyHOLD. Contestants hope that each of their picks will have a higher share price at contest end next year, with buyouts/M and A activity at multiples of entry values a possibility.
      👍️ 1 💩 1
      IgnoranceIsBliss IgnoranceIsBliss 10 hours ago
      I'm tastytheelf by the way. MRM made me change my handle.
      👍️ 3 🤡 1
      IgnoranceIsBliss IgnoranceIsBliss 10 hours ago
      If they are maintaining a $50mm buyback (we'll have to see what they say in the Q2 earnings call), and they want to do it like grown-up companies do, then they'd stretch it out over like 6 months to a year, and there would be some opportunism to it.

      You'd be looking at 250k to 500k shares per trading day I would think. Right now that would distort the market and drive the price up.
      👍️0
      IgnoranceIsBliss IgnoranceIsBliss 10 hours ago
      It should be! It isn't some kind of Frankenstein gene-altering, cancer-causing chemical -- it's a natural extract!
      👍️0
      JRoon71 JRoon71 11 hours ago
      Nice find Dogn, thank you.

      Efficacy - CHECK!
      MO Placebo Issue Debunked - CHECK!
      AFib Risk Debunked - CHECK!
      👍️ 3
      CaptBeer CaptBeer 17 hours ago
      The Absolute Risk of these two AE’s in trial vs. placebo were very low to begin with. It appears that in the RW the risk is nearly zero.

      V is possibly the safest of any CV drug while delivering efficacy >= statins and cost effectiveness 3-5X than PCSK-9’s.
      👍️ 3
      CaptBeer CaptBeer 18 hours ago
      Our Friend, Dr John Nelson once again brilliantly showing the consistency of REDUCE-IT data and how safe VASCEPA/VAZKEPA is in the Real World. All the negative hype about bleeding and Afib with IPE is laid to rest.
      👍️ 2
      ramfan60 ramfan60 18 hours ago
      Great positive example of the V safety profile. The real world data shows far less adverse events than the Reduce-It study results.
      👍️ 1
      dogn dogn 20 hours ago
      Journal of Clinical Lipidology
      Volume 18, Issue 4, Supplement, July–August 2024, Page e574

      Comparison of Package Insert versus Real World Safety Data from Branded Icosapent Ethyl Users: A Select Analysis Utilizing MarketScan Data.

      https://www.sciencedirect.com/science/article/abs/pii/S1933287424001594

      Conclusions
      RWD demonstrated trends in the frequency of IPE-labeled AEs that are consistent with, but 3-5x lower than, trial and labeling data. Potential reasons for consistently lower AE rates in RWD compared with trial data may be related to differences in how AEs are assessed and documented in the real world vs. in trials.
      👍️ 5
      FlyFishingStocks FlyFishingStocks 23 hours ago
      October 25, 2021 Amarin closed at 4.77. Who was running the company? Who was in the Whitehouse? Screwing with the interest rates and giving $Billions to Ukraine? We were neck deep with Covid as well. Perfect storm?

      Well, if it has been such a "perfect storm," how do you answer the biotech group index rising from 62.05 to the high today of 102.11 over the past 2 years (a + 65% increase)? AMRN, on the other hand, over that same time frame eroded 64% of its share value; exactly the opposite of its index. That debunks your Whitehouse resident, CEO, Billions to Ukraine, interest rate screw job, and Covid theory.

      "Get a life" man.
      👍️ 1
      hayward hayward 23 hours ago
      FlyFishingStocks

      Still think the buy back is in progress ? Total volume today less then 400,000 shares traded TIA

      Michael
      👍️0
      marzan marzan 23 hours ago
      FFS, should we add more, hold, or sell before the Q next Wednesday. What does the chart say? Thanks in advance.
      👍️0
      Nukemtiltheyglow Nukemtiltheyglow 1 day ago
      October 25, 2021 Amarin closed at 4.77. Who was running the company? Who was in the Whitehouse? Screwing with the interest rates and giving $Billions to Ukraine? We were neck deep with Covid as well. Perfect storm?
      👍️0
      Nukemtiltheyglow Nukemtiltheyglow 1 day ago
      I’ll answer for Irish; it’s called who resides in the Whitehouse!!! And who was at the helm 2 years ago when the stock cratered.

      Jesus man get a life.
      👍️0
      FlyFishingStocks FlyFishingStocks 1 day ago
      Still waiting mr. denial for your opinion as to why/how the stock price plunged from $4.50 to .65 spanning the time of Denner's involvement to date.

      Do you not have an answer?
      👍️0
      Jasbg Jasbg 1 day ago
      JR, Have to agree with you here. Denner and Sarissa 'likely have a lot of influence' on how Amarin is run - but as you said 'Denner is NOT on the board'.

      And Hedge Funds works often in 'teams' - no way anyone can say that Sarissa is (not though partners) shorting Amarin - if they valuate that to be the best short term way to do business / make money.
      -------------------------

      And I am with you all the way - that Sarissa and Denner have 'big long term plans' for Amarin.

      I like $10- 15 better than $5. BO announcement will be there some day - 2025 - 26 - not unlikely, if besides UK - a couple of other big countries in EU and possibly China - will start to create noticeable revenue ✌️
      👍️0
      Number sleven Number sleven 1 day ago
      DAR, The case I posted looks like it might be Canadian. If so, it doesn't represent a precedent we can use.
      CAFC has already ruled on the appeal.
      Sleven,
      👍️ 1
      DAR53 DAR53 1 day ago
      NS, thanks for the link. So based upon this case, it would appear to me that no only is Hikma infringing (case ongoing), but the other generics could be found guilty of infringement against Amarin. The skinny label is certainly be infringed upon in the CVD area regardless of the fault of doctors, insurers or PBMs. Amarin has to gain traction on some of these legal cases as precedent.
      I don't recall the date for the Hikma / Amarin CAFC official response. Is that August 13?
      👍️0
      ramfan60 ramfan60 1 day ago
      Lowest volume day that I can remember..... will be interesting to see what happens in the next 8 mins
      👍️0
      Number sleven Number sleven 1 day ago
      JRoon, I will find and post the actual ruling later. This infringement case is almost identical to the situation that Amarin is in. The generic companies have a mono therapy label. Our label involves combination therapy. Ths is the same situation as the case I posted. Apotex was found guilty of inducing infringement because the majority of patients being treated were given combination therapy.
      Sleven,
      👍️ 3
      irishpaddy irishpaddy 1 day ago
      Hey mister come afterwards
      Laws are laws and board directors are well aware of where Bernie Madoff ended up...of course companies short but Sarissa Denner in this case cannot. You know zero about what I have held or not held, you of 0000's of posts on 1 stock...
      Why would you only discuss one stock if you actually knew trading...with graphs handles tails of yours but only 1 stock..
      We know what you are ..

      👍️0
      JRoon71 JRoon71 1 day ago
      Good find, Sleven.

      The last paragraph was interesting:
      This case suggests that, in order to succeed in “skinny label” cases, a generic manufacturer may need to overcome established prescribing practices, which may be influenced not only by the patentee’s label but its market tenure as well.
      👍️0
      FlyFishingStocks FlyFishingStocks 1 day ago
      Hey thur mr. denial. Let's hear your opinion as to why/how the stock price plunged from $4.50 to .65 spanning the time of Denner's involvement to date. Be sure to lace it with facts (as you demand of other posters).

      Based on my opinion/strategy (which I'm sure you are aware of), I am shocked you have held your shares clear down to the bottom - especially since you proclaim to be so smart. You have chosen to see the AMRN investment completely opposite to my thinking, but that's your opinion. Differing opinions are the very ingredients that make up a 'market' composed of buyers and sellers. That's why companies like Sarissa can exploit FOMO retail and become filthy wealthy.

      Don't overdose on your grumpy pills.
      👍️ 1
      Number sleven Number sleven 1 day ago
      https://www.torys.com/en/our-latest-thinking/publications/2023/12/lr-2023/federal-court-of-appeal-skinny-label-case-highlights-the-potential-power-of-the-patentee
      Sleven,
      👍️0
      JRoon71 JRoon71 1 day ago
      Kiwi, no disclosure of buyback yet. And no filings. So "officially", no shares purchased yet. But there's still the possibility that Cantor is buying and accumulating in their own account, and have not transferred shares to Amarin yet. I imagine Amarin will need to explain where they are in the process at the CC next week.

      As far as shorting, you are correct, board member cannot short. However, this does not prohibit Sarissa (the investment firm) from shorting (as they stated in their proxy) until they reach 10% ownership. It also does not prevent any "partners" from shorting.

      But they would not state in their SEC filing that they could potentially short the stock, if that were illegal.
      👍️ 1
      Whalatane Whalatane 1 day ago
      RMB My quick take is that most companies prohibit members of the BOD from shorting their Co's stock ...for reasons mentioned by others here .
      However there maybe loop holes that Denner / Sarissa are using to short if they wanted to....and they have disclosed as such .

      What I think is more significant is has AMRN disclosed any buy back purchases yet ?
      I've been on vacation so haven't followed the board much lately .
      Any news on the share buyback ?
      Kiwi
      👍️0
      JRoon71 JRoon71 1 day ago
      Yeah, I was just commenting on the thread in general.
      👍️0
      irishpaddy irishpaddy 1 day ago
      Rainy

      Just go away
      Soft sly bashing
      Anyone connected in any way with Sarissa / Dinner would be put away for years for that.
      Consistently you suggest the most idiotic unbelievably stupid ideas as if you had intellect.
      To school boy now
      👍️0
      rosemountbomber rosemountbomber 1 day ago
      I wasn’t speaking to any of those questions or points, only trying clear up any possible confusion as to whether the 10% applied to directors - in any public company.
      👍️0
      Chromosome Chromosome 1 day ago
      Anyone on a BoD that shorts the stock of the company they are charged with as a fiduciary should be fired immediately, regardless of legality. I have never heard of anyone on a BoD do that.
      👍️0
      JRoon71 JRoon71 1 day ago
      Who said anyone on the board was doing this directly?

      Also, Alex Denner is not on the Board.
      👍️0
      irishpaddy irishpaddy 1 day ago
      Rose

      Yes exactly
      BOD must declare irrespective of the size of their holdings. It would plainly be insider trading as they would have knowledge before anyone else.
      👍️0
      rosemountbomber rosemountbomber 1 day ago
      Kiwi, not sure if it was because I knew 3 languages before starting kindergarten, but I seemed to have a bit of difficulty with comprehension.

      So maybe I am not clear on this, but the SEC rule you posted, I understand to mean that the 10% only applies to shareholders. Otherwise, executives or directors (BOD) would have to declare before shorting the way I comprehend it, right?
      👍️0
      Whalatane Whalatane 1 day ago
      Section 16 of the Securities Exchange Act of 1934:
      Under Section 16, executive officers, directors, and significant shareholders (those owning more than 10% of the company's stock) must file public reports disclosing their holdings and transactions in the company's equity securities. Transactions must be reported within two business days using Form 4

      Kiwi
      👍️ 1
      Meowza Meowza 1 day ago
      Thank you for belying the bipolar egomaniacal cardiologist stereotype.
      👍️0
      irishpaddy irishpaddy 1 day ago
      Ruin
      Nope
      Sarissa as an investment entity may short declare able shareholdings which they state in their company information. Once they take up board positions they become insiders and as such if they were to even intend to short or go long they must declare that intent in advance.
      Ruiny back to school boy.
      👍️0
      north40000 north40000 1 day ago
      Readers may want to look at/skim read a willful infringement, damages case/opinion released Tuesday this past week in the E.D Texas after entry of redactions:

      NETLIST v. SAMSUNG et al

      Post # 24778 on the NETLIST IHub board.

      About $500,000,000 damages found by a jury. Different facts and patents of course, but note that Hikma(like Samsung) does continue to sell product after filing of Amarin complaint. Will Hatch Waxman make a difference? Reread the recent CAFC opinion in Amarin v. Hikma.
      👍️ 1

      Your Recent History

      NASDAQ
      AMRN
      Amarin
      NYSE
      GME
      GameStop
      NASDAQ
      JRVR
      James River
      COIN
      TUSDBTC
      TrueUSD
      BOV
      MNPR3
      MINUPAR ON
      EU
      MTRK
      MotorK
      TSXV
      JWCA
      James E Wagner Cultivation
      Delayed Upgrade Clock